PROCEPT BioRobotics Corporation Research and Development Expense
PROCEPT BioRobotics Corporation (PRCT) reported Research and Development Expense of $20.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- PROCEPT BioRobotics Corporation research and development expense for the quarter ending 2026-06-30 was $20.10M, a 14.00% increase year-over-year.
- PROCEPT BioRobotics Corporation research and development expense for the quarter ending 2026-03-31 was $21.46M, a 30.87% increase year-over-year.
- PROCEPT BioRobotics Corporation research and development expense for the quarter ending 2025-12-31 was $19.06M, a 26.48% increase year-over-year.
- PROCEPT BioRobotics Corporation research and development expense for the quarter ending 2025-09-30 was $18.19M, a 9.25% increase year-over-year.
- PROCEPT BioRobotics Corporation research and development expense for fiscal 2025 was $71.28M, a 14.41% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation research and development expense for fiscal 2024 was $62.30M, a 28.59% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation research and development expense for fiscal 2023 was $48.45M, a 67.16% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation research and development expense for fiscal 2022 was $28.98M, a 52.59% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.10M 10-Q · filed 2026-08-05 | $41.57M 10-Q · filed 2026-08-05 | $60.62M derived: sum of 3 quarters · filed 2026-08-05 | $78.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $21.46M 10-Q · filed 2026-04-30 | $40.52M derived: sum of 2 quarters · filed 2026-04-30 | $58.71M derived: sum of 3 quarters · filed 2026-04-30 | $76.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $19.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.24M derived: sum of 2 quarters · filed 2026-02-26 | $54.88M derived: sum of 3 quarters · filed 2026-08-05 | $71.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $18.19M 10-Q · filed 2025-11-05 | $35.82M derived: sum of 2 quarters · filed 2026-08-05 | $52.22M 10-Q · filed 2025-11-05 | $67.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $17.63M 10-Q · filed 2026-08-05 | $34.03M 10-Q · filed 2026-08-05 | $49.10M derived: sum of 3 quarters · filed 2026-08-05 | $65.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.40M 10-Q · filed 2026-04-30 | $31.47M derived: sum of 2 quarters · filed 2026-04-30 | $48.12M derived: sum of 3 quarters · filed 2026-04-30 | $65.62M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $15.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.71M derived: sum of 2 quarters · filed 2026-02-26 | $49.21M derived: sum of 3 quarters · filed 2026-02-26 | $62.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.65M 10-Q · filed 2025-11-05 | $34.15M derived: sum of 2 quarters · filed 2025-11-05 | $47.23M 10-Q · filed 2025-11-05 | $61.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $17.50M 10-Q · filed 2025-08-07 | $30.59M 10-Q · filed 2025-08-07 | $45.08M derived: sum of 3 quarters · filed 2026-02-26 | $56.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $13.08M 10-Q · filed 2025-05-02 | $27.58M derived: sum of 2 quarters · filed 2026-02-26 | $39.18M derived: sum of 3 quarters · filed 2026-02-26 | $50.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.10M derived: sum of 2 quarters · filed 2026-02-26 | $37.71M derived: sum of 3 quarters · filed 2026-02-26 | $48.45M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.60M 10-Q · filed 2024-10-28 | $23.21M derived: sum of 2 quarters · filed 2024-10-28 | $33.95M 10-Q · filed 2024-10-28 | $43.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $11.61M 10-Q · filed 2024-08-02 | $22.35M 10-Q · filed 2024-08-02 | $32.03M derived: sum of 3 quarters · filed 2025-02-27 | $39.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $10.74M 10-Q · filed 2024-05-02 | $20.42M derived: sum of 2 quarters · filed 2025-02-27 | $28.00M derived: sum of 3 quarters · filed 2025-02-27 | $34.71M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $17.26M derived: sum of 2 quarters · filed 2025-02-27 | $23.97M derived: sum of 3 quarters · filed 2025-02-27 | $28.98M 10-K · filed 2025-02-27 |
| 2022-09-30 | $7.58M 10-Q · filed 2023-11-02 | $14.29M derived: sum of 2 quarters · filed 2023-11-02 | $19.30M 10-Q · filed 2023-11-02 | $24.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $6.71M 10-Q · filed 2023-07-28 | $11.72M 10-Q · filed 2023-07-28 | $16.79M derived: sum of 3 quarters · filed 2024-02-28 | $21.71M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $5.01M 10-Q · filed 2023-05-04 | $10.09M derived: sum of 2 quarters · filed 2024-02-28 | $15.01M derived: sum of 3 quarters · filed 2024-02-28 | $19.48M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $9.99M derived: sum of 2 quarters · filed 2024-02-28 | $14.47M derived: sum of 3 quarters · filed 2024-02-28 | $18.99M 10-K · filed 2024-02-28 |
| 2021-09-30 | $4.92M 10-Q · filed 2022-11-04 | $9.39M derived: sum of 2 quarters · filed 2022-11-04 | $13.92M 10-Q · filed 2022-11-04 | $18.46M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $4.48M 10-Q · filed 2022-08-05 | $9.00M 10-Q · filed 2022-08-05 | $13.54M derived: sum of 3 quarters · filed 2022-08-05 | $17.43M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $4.52M 10-Q · filed 2022-05-06 | $9.06M derived: sum of 2 quarters · filed 2022-05-06 | $12.96M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $8.44M derived: sum of 2 quarters · filed 2022-03-22 | $16.27M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $3.89M 10-Q · filed 2021-11-05 | $11.73M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |